Over the past few years, studies have increasingly documented the contribution of IGF2BP3 to tumor cell proliferation, blocking apoptosis, favoring stemness, promoting migration and drug resistance, and IGF2BP3 overexpression has been widely associated with adverse patient outcomes in many different tumors [43]. This evidence concerns the gene IGF2BP3 and neoplasm.